Evidence map›Paper›PMID 25988130›Full record

ArticleFrontiers in nutrition2014

The Pentapeptide RM-131 Promotes Food Intake and Adiposity in Wildtype Mice but Not in Mice Lacking the Ghrelin Receptor.

Katrin Fischer, Brian Finan, Christoffer Clemmensen, Lex H T van der Ploeg, Matthias H Tschöp, Timo D Müller

Open access · goldAbstract read
In one paragraph

Article in Frontiers in nutrition, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Article
  3. Therapeutic Potential of Targeting the Ghrelin Pathway.International journal of molecular sciences · 2017
    Review
  4. Review
  5. Ghrelin and motilin receptors as drug targets for gastrointestinal disorders.Nature reviews. Gastroenterology & hepatology · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Katrin FischerInstitute for Diabetes and Obesity (IDO) and Helmholtz Diabetes Center, Helmholtz Center Munich, German Research Center for Environmental Health (GmbH) , Neuherberg , Germany ; Division of Metabolic Diseases, Department of Medicine, Technische Universität München , Munich , Germany.
Brian FinanInstitute for Diabetes and Obesity (IDO) and Helmholtz Diabetes Center, Helmholtz Center Munich, German Research Center for Environmental Health (GmbH) , Neuherberg , Germany ; Division of Metabolic Diseases, Department of Medicine, Technische Universität München , Munich , Germany.
Christoffer ClemmensenInstitute for Diabetes and Obesity (IDO) and Helmholtz Diabetes Center, Helmholtz Center Munich, German Research Center for Environmental Health (GmbH) , Neuherberg , Germany ; Division of Metabolic Diseases, Department of Medicine, Technische Universität München , Munich , Germany.
Lex H T van der PloegRhythm Pharmaceuticals Inc. , Boston, MA , USA.
Matthias H TschöpInstitute for Diabetes and Obesity (IDO) and Helmholtz Diabetes Center, Helmholtz Center Munich, German Research Center for Environmental Health (GmbH) , Neuherberg , Germany ; Division of Metabolic Diseases, Department of Medicine, Technische Universität München , Munich , Germany.
Timo D MüllerInstitute for Diabetes and Obesity (IDO) and Helmholtz Diabetes Center, Helmholtz Center Munich, German Research Center for Environmental Health (GmbH) , Neuherberg , Germany ; Division of Metabolic Diseases, Department of Medicine, Technische Universität München , Munich , Germany.
Technical University of Munich · DEHelmholtz Zentrum München · DERhythm (United states) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The gastrointestinal peptide hormone ghrelin is the endogenous ligand of the growth hormone secretagogue receptor (a.k.a. ghrelin receptor, GHR). Currently, ghrelin is the only circulating peripheral hormone with the ability to promote a positive energy balance by stimulating food intake while decreasing energy expenditure and body fat utilization, as defined in rodents. Based on these and additional, beneficial effects on metabolism, the endogenous ghrelin system is considered an attractive target to treat diverse pathological conditions including those associated with eating/wasting disorders and cachexia. As the pharmacological potential of ghrelin is hampered by its relatively short half-life, ghrelin analogs with enhanced pharmacokinetics offer the potential to sustainably improve metabolism. One of these ghrelin analogs is the pentapeptide RM-131, which promotes food intake and adiposity with higher potency as compared to native ghrelin in rodents. Whereas, the effect of RM-131 on energy metabolism is solidly confirmed in rodents, it remains elusive whether RM-131 exerts its effect solely via the ghrelin receptor. Accordingly, we assessed the receptor specificity of RM-131 to promote food intake and adiposity in mice lacking the GHR. Our data show that in wildtype mice RM-131 potently promotes weight gain and adiposity through stimulation of food intake. However, RM-131 fails to affect food intake and body weight in mice lacking the GHR, underlining that the anabolic effects of RM-131 are mediated via the ghrelin receptor in mice.

Indexed as

adiposityfood intakeGHRghrelinGHSR1aRM-131

Identifiers

PMID25988130
PMCPMC4428373
OpenAlexW2093332183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.